Glucocorticoids Relieve Collectin-Driven Suppression of Apoptotic Cell Uptake in Murine Alveolar Macrophages through Downregulation of SIRP α

Alexandra L. McCubbrey, Joanne Sonstein, Theresa M. Ames, Christine M. Freeman and Jeffrey L. Curtis

*J Immunol* 2012; 189:112-119; Prepublished online 21 May 2012;
doi: 10.4049/jimmunol.1200984
http://www.jimmunol.org/content/189/1/112

Supplementary Material

http://www.jimmunol.org/content/suppl/2012/05/21/jimmunol.1200984.DC1

References

This article cites 63 articles, 27 of which you can access for free at:
http://www.jimmunol.org/content/189/1/112.full#ref-list-1

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

*average

Subscription

Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Glucocorticoids Relieve Collectin-Driven Suppression of Apoptotic Cell Uptake in Murine Alveolar Macrophages through Downregulation of SIRPα

Alexandra L. McCubbrey,* Joanne Sonstein,† Theresa M. Ames,† Christine M. Freeman,†‡ and Jeffrey L. Curtis*,†‡

The lung environment actively inhibits apoptotic cell (AC) uptake by phagocytes, also termed efferocytosis (1), an essential process that promotes the resolution of injury and inflammation, facilitating tissue repair in the lung and throughout the body (2). Impaired AC uptake has been found in phagocytes from human subjects with cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD) (3–6). Because defective AC clearance clearly contributes to autoimmunity in murine models (7, 8), and because there is growing evidence that human emphysema may have an autoimmune component (9, 10), potential therapies designed to bolster AC clearance improve lung health.

A poptotic cell (AC) uptake by phagocytes, also termed efferocytosis (1), is an essential process that promotes the resolution of injury and inflammation, facilitating tissue repair in the lung and throughout the body (2). Impaired AC uptake has been found in phagocytes from human subjects with cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD) (3–6). Because defective AC clearance clearly contributes to autoimmunity in murine models (7, 8), and because there is growing evidence that human emphysema may have an autoimmune component (9, 10), potential therapies designed to bolster AC clearance have been proposed (11). This issue is of considerable importance, because COPD is now the third leading cause of death in the United States, and has been projected by the World Health Organization to become the leading worldwide cause of death by mid-21st century (12).

In seeming contradiction to the importance of AC clearance, the resident lung phagocyte, alveolar macrophages (AMøs), bind and engulf AC less avidly than do other professional phagocytes (13–15). Reduced efferocytosis by AMø results, in part, from very restricted adhesion pathway usage and markedly decreased expression of PKC ΒII (15, 16). Importantly, however, the normal lung environment actively suppresses the ability of AMøs to ingest AC, because of the inhibitory action of specific surfactant proteins, the lung collectins surfactant protein A (SP-A) and SP-D, through their interaction with signal regulatory protein α (SIRPα; CD172a) (17). This inhibitory effect persists in vitro for days after AMø removal from the lung environment. Whether increasing the ability of AMøs to ingest AC would have beneficial health effects is unproved, but better understanding of how the unique mechanisms by AMø interact with AC uptake is essential to guide the development of any such future therapies.

Several pharmacological treatments can increase AC uptake in vitro. Glucocorticoids (GCs) have been shown to increase in vitro AC uptake by human blood-derived monocytes, macrophage (Mø) cell lines, and, in a single report, human AMøs (5, 18). In human blood-derived monocytes, this increase is dependent on MerTk, increased Rac phosphorylation, and altered surface sialylation (19–21). It is unclear whether GCs act via these mechanisms in other cell types such as AMøs. Defining whether and how GCs and other agents increase AC uptake by murine AMø is an essential step to develop murine models to test whether manipulating AC clearance improves lung health.

In this study, we report that the potent GC fluticasone increased AC uptake by murine AMø in a rapid, dose-dependent fashion through downregulation of SIRPα. Our data show a novel facet of...
GC action: a rapid decrease in the sensitivity of murine AMs to the collectin-rich, inhibitory environment of the lung, thus lifting tonic inhibition and increasing AC uptake.

Materials and Methods

Mice

We purchased C57BL/6 mice from Charles River Laboratories. Mice were housed under specific pathogen-free conditions and used for experiments between 8 and 16 wk of age. Animal care and experimentation were conducted in accordance with U.S. Department of Health and Human Services Guide for the Care and Use of Laboratory Animals and were approved by the Animal Use Committee at Veterans Affairs Ann Arbor Healthsystem.

Cell isolation and culture conditions

We isolated alveolar cells by bronchoalveolar lavage using 10 ml PBS containing 0.5 mM EDTA (14). AMs were adhesion purified from this population; nonadherent cells were discarded after 1.5 h of culture. Unstimulated peritoneal cells were isolated by peritoneal lavage using 7–10 ml PBS containing 0.5 mM EDTA, administered in 1- to 2-ml aliquots. Peritoneal macrophages (PMs) were adhesion purified from this depleted population; nonadherent cells were discarded after 45 min of culture.

All culture was performed in a 5% CO2 environment at 37°C. During adhesion purification, phagocytosis, and adhesion assays, AMs were cultured in 10% FBS, 1 mM sodium pyruvate, 0.5 mM 2-ME, 1 mM HEPES, 100 U/ml penicillin, 100 U/ml streptomycin, 0.292 mg/ml l-glutamine in RPMI. During all other treatments, Møs were cultured in AIM-V (Life Technologies) without serum.

Induction of thymocyte apoptosis and SRBC opsonization

To induce apoptosis, in most experiments, we treated single-cell suspensions of murine thymocytes with 10 μM dexamethasone (Sigma) for 4.5 h. These conditions consistently produced 50–60% Annexin+ cells (as we have previously shown (22). In selected experiments, thymocytes were UV-irradiated using a gel box (FOTO/ultraviolet technology) without serum.

Phagocytosis and adhesion assays

We quantified AC phagocytosis and adhesion as previously described (14). In brief, Møs were cultured in 8-well Permavox chamber slides (Nunc, Roskilde, Denmark). We quantified AC phagocytosis and adhesion as previously described (14). We quantified AC phagocytosis and adhesion as previously described (14). We quantified AC phagocytosis and adhesion as previously described (14). We quantified AC phagocytosis and adhesion as previously described (14). We quantified AC phagocytosis and adhesion as previously described (14).

Flow cytometry

AMs were cultured in 48-well tissue culture plates at 105 cells/well with 2 μM fluticasone, 10 μM simvastatin, 500 ng/ml azithromycin, or control media for 6–24 h. Cells were released from culture plates using the dissociation enzyme TrypLE (Invitrogen) and stained after Fc-block with a panel of fluorochrome-conjugated Abs as previously described (24). The following anti-murine Abs were used (clone; source): CD45 (30-F11; BD), TCRβ (57-597; BD), CD19 (MCA1439F; AB Serotec), CD11c (N418; eBioscience), CD11b (MI70; eBioscience), and SIRPα (P84; BD).

Experiments were performed on an LSR II flow cytometer (BD Bioscience, San Jose, CA), equipped with the following lasers (numbers) and their associated filter sets (letters): (1) 488 nm blue (primary laser), (a, b) 550 nm long-pass (LP), 530/30 nm short band-pass (SBP), (b) 685 nm LP, 695/40 nm SBP; (2) 405 nm violet laser, (a, c) 505 nm LP, 530/30 nm band-pass (BP), (d) 450/50 nm PB; (3) 633 nm red HeNe laser, (e) 735 nm LP, 780/60 nm SBP, (f) 685 nm LP, 710/50 nm SBP; (g) 660/20 nm BP; and (h) 561 nm yellow-green laser, (b) 735 nm LP, 780/60 SBP, (i) 685 nm LP, 710/50 SBP, (j) 635 nm LP, 610/20 nm SBP, (k) 581/15 nm BP. In all experiments, we used isotype-matched controls and collected a minimum of 10,000 CD45+ viable events per sample. Data were collected on an HP XW4300 Workstation (Hewlett-Packard, Palo Alto, CA) using FCaSDiva software (version 6.1.3; BD Biosciences) with automatic compensation and were analyzed using FlowJo software (Tree Star, Ashland, OR) on an Intel iMac computer (Apple, Cupertino, CA).

Statistical analyses

We calculated significance using one-way ANOVA with Bonferroni post hoc testing or using Student t test where appropriate using GraphPad Prism4 (La Jolla, CA) on an Intel iMac computer. Results were considered significant at p < 0.05.

Results

Potent GC rapidly increases murine AM phagocytic activity and binding of AC

To study the effect of GCs used clinically as inhaled corticosteroids (ICSs) on AC uptake by murine AMs, we first performed in vitro phagocytosis assays after treatment with the potent GC fluticasone (Fig. 1A, Supplemental Fig. 1A, 1B). Pretreatment with fluticasone significantly increased the ability of murine AMs to ingest AC after only 3 h, with peak effect by 6 h (Fig. 1B, 1C). The magnitude of the effect was dose responsive, increasing with higher doses of fluticasone; significance could be seen at 2 μM (Fig. 1D, 1E). Fluticasone treatment also increased AM uptake of UV-killed thymocytes (Supplemental Fig. 1C, 1D), implying that the effect did not depend on the method used to induce apoptosis. This profferocytic effect was not restricted to fluticasone, because increased AM AC uptake could also be seen after treatment with budesonide, another potent GC used clinically (percentage phagocytosis: untreated 16.5 ± 3.4% versus budesonide 38.6 ± 4.0%; phagocytic index: untreated 0.19 ± 0.04 versus budesonide 0.51 ± 0.09; mean ± SE of 3 mice assayed individually in two independent experiments; both measurements significant, p < 0.05 by one-way ANOVA with Bonferroni post hoc testing). In contrast, AC uptake by resident murine PMs did not increase on fluticasone treatment (Supplemental Figs. 2A, 4B), even on treatment up to 6 h (data not shown). In addition, fluticasone did not increase Fc-mediated clearance of IgG-opsonized SRBC (Supplemental Figs. 2C, 4D) or of 4-μm latex microspheres (data not shown) by murine AMs.

To study the effect of GCs on murine AM binding of AC, we next performed adhesion assays (Fig. 1F). Similar to the effect on AC engulfment, 4-h treatment with fluticasone significantly increased the ability of murine AMs to bind ACs, with the effect peaking by 6 h (Fig. 1G, 1H). The magnitude of the effect was...
Steroids relieve suppressed AC uptake by murine AMøs

Fluticasone initiates reprogramming toward a proclearance phenotype and increases AC uptake without a requirement for new protein synthesis

GCs alter expression of large numbers of target genes, for the most part via the specific GC receptor GRs, a member of the ligand-regulated family of nuclear receptors (25), but also by incompletely understood translation-independent mechanisms (26, 27). To begin to define how fluticasone upregulates murine AMø uptake of ACs, we assessed the expression of several genes known to be involved in AC clearance, including Mertk and Axl, members of the TAM family of receptor tyrosine kinases (28), CD91/LRP (29), and the negative regulator SIRPs (17). We also examined mRNA expression of the nuclear receptor PPARγ, a positive regulator of the expression of opsonins involved in bridging ACs and of Mø surface receptors including Mertk (30). Within 3 h of fluticasone treatment, Mertk mRNA significantly increased, whereas Sirps transcripts significantly decreased (Fig. 2A). These changes are consistent with an induction by GCs of proclearance AMø phenotype, as previously described for human monocytes (31). Transcripts for Axl, LRP, and PPARγ did not change during this period of fluticasone treatment.

Thus, GC pretreatment is associated with rapidly increased AC binding and engulfment that is specific to AMøs and not observed in a resting, fully differentiated tissue Mø from another mucosal surface. Furthermore, the ability to increase AC uptake appears to be a class effect of potent GC, which, however, does not alter phagocytosis by murine AMøs of other types of particles.

Fluticasone decreases protein expression of SIRPs

To test the significance of the observed fluticasone-induced gene repression of SIRPs (Fig. 2A), we examined protein expression of SIRPs. Using flow cytometry, we found that surface expression of SIRPs was decreased within 6 h of fluticasone treatment, with statistical significance reached by 24 h (Fig. 2C, 2D).

We also tested the involvement of several pathways that have been implicated in AC uptake by other types of tissue Møs, using pharmacological inhibitors or blocking mAbs. Neither fluticasone-treated AMøs nor, as we have previously described, untreated also dose responsive; significance could be seen at doses >200 pM (Fig. II, 1J). To determine whether fluticasone initiated novel adhesion pathways, we pretreated AMøs with mAbs to block CD11c and CD18, which we have previously shown mediate the majority of adhesion of ACs to murine AMøs (15). Blocking either integrin subunit reduced AMø binding to ACs, regardless of treatment with fluticasone (Supplemental Fig. 3). In contrast, similar to the lack of effect on engulfment, fluticasone treatment did not increase PMø binding to ACs regardless of fluticasone dose (2 pM to 2 μM) or duration of treatment to 6 h (data not shown).

Thus, GC pretreatment is associated with rapidly increased AC binding and engulfment that is specific to AMøs and not observed in a resting, fully differentiated tissue Mø from another mucosal surface. Furthermore, the ability to increase AC uptake appears to be a class effect of potent GC, which, however, does not alter phagocytosis by murine AMøs of other types of particles.

Fluticasone initiates reprogramming toward a proclearance phenotype and increases AC uptake without a requirement for new protein synthesis

GCs alter expression of large numbers of target genes, for the most part via the specific GC receptor GRs, a member of the ligand-regulated family of nuclear receptors (25), but also by incompletely understood translation-independent mechanisms (26, 27). To begin to define how fluticasone upregulates murine AMø uptake of ACs, we assessed the expression of several genes known to be involved in AC clearance, including Mertk and Axl, members of the TAM family of receptor tyrosine kinases (28), CD91/LRP (29), and the negative regulator SIRPs (17). We also examined mRNA expression of the nuclear receptor PPARγ, a positive regulator of the expression of opsonins involved in bridging ACs and of Mø surface receptors including Mertk (30). Within 3 h of fluticasone treatment, Mertk mRNA significantly increased, whereas Sirps transcripts significantly decreased (Fig. 2A). These changes are consistent with an induction by GCs of proclearance AMø phenotype, as previously described for human monocytes (31). Transcripts for Axl, LRP, and PPARγ did not change during this period of fluticasone treatment.

These mRNA changes not withstanding, the rapid kinetics of increased AC uptake in murine AMøs led us to postulate that fluticasone may act on a short-lived inhibitor. To test that possibility, we blocked new protein synthesis using cycloheximide. Treatment of AMøs with cycloheximide before an additional 5-h fluticasone treatment did not abrogate the increase in AC uptake (Fig. 2B).

Thus, although Mertk and likely other AC recognition molecules changes are consistent with an induction by GCs of proclearance AMø phenotype, as previously described for human monocytes (31). Transcripts for Axl, LRP, and PPARγ did not change during this period of fluticasone treatment.

These mRNA changes not withstanding, the rapid kinetics of increased AC uptake in murine AMøs led us to postulate that fluticasone may act on a short-lived inhibitor. To test that possibility, we blocked new protein synthesis using cycloheximide. Treatment of AMøs with cycloheximide before an additional 5-h fluticasone treatment did not abrogate the increase in AC uptake (Fig. 2B).

Thus, although Mertk and likely other AC recognition molecules

Fluticasone decreases protein expression of SIRPs

To test the significance of the observed fluticasone-induced gene repression of SIRPs (Fig. 2A), we examined protein expression of SIRPs. Using flow cytometry, we found that surface expression of SIRPs was decreased within 6 h of fluticasone treatment, with statistical significance reached by 24 h (Fig. 2C, 2D).

We also tested the involvement of several pathways that have been implicated in AC uptake by other types of tissue Møs, using pharmacological inhibitors or blocking mAbs. Neither fluticasone-treated AMøs nor, as we have previously described, untreated

statistically significant for untreated, p < 0.01 by one-way ANOVA with Bonferroni post hoc testing.
murine AMs require CD36, αV integrin, or autocrine prostanoid signaling for AC uptake (Supplemental Fig. 4A–F). These results complement those in which we blocked CD11c and CD18 (Supplemental Fig. 3) in indicating that GC-augmented AC uptake does not require engagement of new adhesion pathways, but instead appears to result from increased efficiency of the same pathways used in the resting state.

Azithromycin, but not simvastatin, has additive effects on efferocytosis

In addition to GCs, AC uptake is known to be increased by other commonly prescribed pharmaceuticals including statins and macrolides (32–34). To study interactions between these medications, we treated murine AMs with combinations of fluticasone, simvastatin, and azithromycin, then assessed the effect on AC engulfment. Treatment with simvastatin or fluticasone alone each increased AC uptake, but the combination had no additive effect (Fig. 3A, 3B). By contrast, treatment of AMs with azithromycin and fluticasone was additive, resulting in near doubling of uptake capacity over either treatment alone (Fig. 3C, 3D).

Simvastatin affects AC uptake via the SIRPα pathway and mechanisms that require new protein translation

The lack of additive effect between simvastatin and fluticasone suggested that these agents likely affect AC uptake through the same molecular pathway. This possibility is supported by previous evidence that statin treatment decreases localization to the plasma membrane of RhoA, a downstream effector of SIRPα signaling; because RhoA antagonizes the essential action of Rac-1 on AC uptake.
uptake, the net effect is increased efferocytosis (23). We used flow cytometry to test whether either simvastatin or azithromycin also affected SIRPα surface expression. Azithromycin did not change SIRPα expression compared with untreated AMøs, but simvastatin significantly decreased SIRPα surface expression after 24 h (Fig. 4A, 4B). However, in contrast with fluticasone, simvastatin did not change SIRPα mRNA levels (data not shown).

To further differentiate possible mechanisms of action, we next blocked induction of new protein synthesis by these two agents. Treatment of murine AMøs with cycloheximide before 24 h of treatment with simvastatin or azithromycin blocked the ability of either agent to increase AC uptake over that of untreated AMøs (Fig. 4C). These results indicate that, unlike fluticasone, both simvastatin and azithromycin do require new protein synthesis to increase AC uptake in AMøs.

**SP-D treatment inhibits AC uptake by PMø, which is reversed with fluticasone treatment**

The inhibitory effect of SIRPα on AC uptake by murine AMøs is tonically maintained by constant exposure in the alveolar space to high concentrations of the lung collectins SP-A and SP-D (17). By contrast, although PMøs express surface SIRPα (35), they receive limited exposure to lung collectins. These considerations led us to hypothesize that the absence of GC-augmented AC uptake by PMøs (Supplemental Fig. 2A, 2B) might reflect limited activation of SIRPα in the peritoneal cavity, which unlike the alveolar spaces, does not contain significant concentrations of SP-A or SP-D. To test this possibility, we first used flow cytometry to test whether SIRPα expression on resident murine PMøs was altered by fluticasone treatment in vitro. Similar to AMøs, 24 h of fluticasone treatment significantly decreased PMøs expression of SIRPα surface protein, whether expressed as percentage positive relative to isotype control or mean fluorescence index (Fig. 5A–C). Next, by pre-incubating PMøs with the SIRPα ligand SP-D, we investigated whether activation of SIRPα could repress AC uptake by murine PMøs. SP-D significantly inhibited AC uptake by PMøs within 4 h (Fig. 5D). Finally, we tested whether fluticasone treatment could rescue decreased PMø AC uptake after SP-D treatment. Although treatment with SP-D alone again significantly inhibited AC uptake, subsequent incubation with fluticasone for 5 h completely reversed this inhibition (Fig. 5D). These results provide a proof-of-concept that the rapid effect of GC on AC uptake by tissue Møs is mediated by release of collectin-induced repression acting via surface SIRPα expression (Fig. 6), and does not depend on GC modification of other features of the AMø phenotype.

**Discussion**

The results of this study identify downregulation on AMøs of the inhibitory receptor SIRPα, which releases them from tonic inhibition by lung collectins, as a novel mechanism by which clinically relevant potent GCs rapidly increase AMø uptake of AC. Using primary murine AMøs, we found that treatment with fluticasone or budesonide increased both binding and uptake of ACs within 2–3 h, without apparent induction of novel adhesive pathways. The effect did not require new protein synthesis, although its magnitude continued to increase through 5–6 h in association with significantly increased Mertk surface expression. Reduced SIRPα surface expression would be fully anticipated to prevent the previously described downstream activation of RhoA, and hence Rho kinase, to inhibit Rac (17), on which AC ingestion crucially depends (36, 37). Although fluticasone treatment of resting murine PMøs did not show the same effect on AC uptake, brief treatment with SP-D induced a significant reduction in their AC uptake that was rapidly reversed by fluticasone. These findings emphasize the importance of the unique lung environment and, thus, more globally, of studying primary phagocytes isolated from mucosal surfaces in attempting to understand host defense of specific organs.

The well-described distinctive characteristics of resident AMøs include a low capacity for AC binding and uptake (13–15). This feature may be of evolutionary value by preventing AC-induced immunosuppression, thus maintaining AMøs as sentinel immune responders. Uptake of AC activates multiple anti-inflammatory pathways within phagocytes, notably through upregulation of SOCS1 and SOCS3, and subsequent inhibition of Jak-STAT signaling (38). The in vivo relevance of such AC-induced suppression on host defense has been shown in a murine model, in which intrapulmonary administration of AC reduced phagocytosis and killing of *Streptococcus pneumoniae*, and impaired leukocyte recruitment through PGE2-EP2-dependent signaling (39). Conversely, the induction of lupus-like autoimmunity in mice by deletions of genes including C1q (40), MFG-E8 (41), αv integrins (42), 43), and the TAM receptors (7, 44–46) argue for concurrent evolutionary pressures to fine-tune AC clearance.

By defining a rapid, translation-independent effect on fully differentiated tissue Møs, these results extend previously described mechanisms of GC actions during Mø differentiation from precursors (18–21, 47, 48). In contrast with the early SIRPα-depen-
dent mechanism we show in mature AMøs, results in those studies required new protein synthesis and more prolonged treatment, maximal when GC was added 3–5 d earlier. Thus, these studies were informative of the effects of systemic steroid treatments on Mø precursors, but not directly relevant to the question about how ICSs might impact functions of resident AMøs. Similarly, two groups have used microarray technology to define the effects of GC on gene regulation during in vitro differentiation of human monocytes (31, 49). They found alterations in a range of molecules plausibly involved in AC clearance, including integrins, scavenger receptors, receptor tyrosine kinases, bridging molecules, molecules associated with engulfment, nuclear receptors, and members of the IFN regulatory family genes. Our finding of upregulation of Mertk transcripts is compatible with the initiation by GCs of such a more prolonged multigene program in AMøs, but the full range of such more delayed effects will require further study.

Our findings agree with and follow directly from recent publications that identified the importance of the alveolar environment to maintain a carefully regulated AMø phenotype (17, 50), particularly in terms of AC uptake. We believe that this line of investigation highlights the ability for elegant control of AMø function by altered expression of key receptors rather than by disruption of this fragile environment. SP-A and SP-D serve at least three functions in the alveolar space: modulating basal AMø signaling in the absence of AC, binding directly to AC to increase their uptake, and as opsonins of multiple lung pathogens (51). Transgenic mice deficient in SP-A or SP-D have increased susceptibility to multiple viral, bacterial, and fungal infections (reviewed in Ref. 52). Deficiency of SP-D can also lead to chronic, low-grade pulmonary inflammation and fibrosis (53). We speculate that regulating SP-A and SP-D signaling by altering SIRPα expression on AMøs, rather than directly by modulation of lung collectin levels, permits the continuation of other signaling and particularly opsonic functions of the lung collectins.

Increased AC uptake by inflammatory Mø in the alveolar spaces occurs in mice treated with intratracheal LPS (17) and has been shown in various phagocytes in vitro using a number of pharmacological agents including GCs, statins, and macrolides. To our knowledge, this is the first report to describe how simultaneous

FIGURE 5. SP-D activates SIRPα pathway in PMøs and makes PMøs sensitive to fluticasone-driven increase in AC clearance. (A–C) Surface SIRPα protein. Murine PMøs were treated with 2 μM fluticasone for 6 or 24 h and then analyzed by flow cytometry for surface expression of SIRPα. Cells shown are gated CD45+CD19+TCRβ. (A) Representative dot plot. (B) Average percentage of CD11b+SIRPα− cells within gated CD11b+ population. (C) Average mean fluorescence index of SIRPα on gated CD11b+ cells. (D) Fluticasone rescues SP-D inhibition of AC uptake. Murine PMøs were treated with 25 μg/ml SP-D for 4 h, followed by control media or 2 μM fluticasone for 5 h; then ACs were added at a 10:1 ratio for 2 h. Slides were washed and stained using H&E; then ingested ACs were counted at ×100 magnification under oil. Data are mean ± SE of five to eight mice assayed individually in at least two independent experiments per condition. **Statistically significant, p < 0.01 by one-way ANOVA with Bonferroni post hoc testing.

FIGURE 6. Model of GC regulation of SIRPα-mediated control of murine AMø efferocytosis. (A) In untreated AMøs, which express high amounts of SIRPα, lung collectins SP-D and SP-A (not shown) signal constitutively through SIRPα, activating SHP-1 and leading to downstream activation of RhoA. By inhibiting Rac-dependent mobilization of actin, the lung collectins tonically impede efficient uptake of ACs by AMøs, even though SP-A and SP-D can also bind ACs. (B) Treatment with fluticasone (triangles) reduces SIRPα surface expression, in part via transrepression of SIRPα by ligand-occupied GR homodimers (brackets). The consequent decreased activation of SHP-1 relieves inhibition of Rac, permitting efficient AC uptake. Based on data in this study, in addition to previously published data (17, 36, 37, 50).
treatment with these drugs, commonly prescribed to individuals with respiratory disease, affects AC uptake in any cell type. The lack of additive effect between simvastatin and fluticasone is congruent with a shared mechanism of action: inhibition of RhoA leading to increased Rac activity. Of more interest is the additive effect of azithromycin and fluticasone on AC uptake, especially given the recent demonstration that azithromycin reduces the frequency of acute exacerbations of COPD (54). The mechanism for the positive effect of azithromycin on AC uptake remains undefined and will require considerable additional investigation; our results imply that azithromycin does not act on RhoA. Decreased AC uptake has been found in AMs from individuals with COPD (6) and asthma (5) when compared with healthy control subjects, which has prompted speculation that poor AC clearance may be contributing to various forms of inflammatory lung diseases. Our work does not address this hypothesis, but it does identify a novel additive interaction between fluticasone and azithromycin that produces a robust increase in AC uptake and may be useful in future therapy.

The finding that SP-D can activate the pre-existing high levels of SIRPα on PMs merits discussion in relation to acute lung injury, in which plasma concentrations of SP-A and SP-D increase significantly and correlate with clinical outcomes (55–57). Sepsis, the most common antecedent of acute lung injury, is associated both with massive apoptosis of circulating lymphocytes and with a delayed immunocompromised state. Results in murine models suggest that the first of these observations may explain the second, via the immunosuppressive effect of AC uptake on innate immunity (58, 59). Although our results strongly imply that SIRPα signaling is not active in resident PMs harvested from untreated mice, they do suggest that increased circulating levels of lung collectins could contribute to reduced efferocytosis throughout the body during acute lung injury. Moreover, signaling via SIRPα also suppresses Mo phagocytosis mediated by FcγRs and complement receptors (60, 61). Thus, the possibility should be investigated that circulating SP-A and SP-D are not only biomarkers of severity during acute lung injury, but might also contribute to systemic immunosuppression that leads to the frequent superinfections that characterize this condition. Considering how GCs affect AMs is particularly important as a result of the widespread prescribing of ICs for the treatment of lung disease. Multiple clinical trials have noted that receiving ICs is associated with increased hospitalization of COPD patients with pneumonia compared with COPD patients receiving nonsteroidal treatment, suggesting ICs treatment results in increased susceptibility to infection (62). In contrast, mice pretreated with fluticasone had significantly reduced lung bacterial burdens 24 and 48 h after Streptococcus pneumoniae infection, suggesting that fluticasone is protective and increases bacterial clearance (63). Our findings in murine AMs and previous findings in human AMs strongly suggest that GC treatment, by increasing AC uptake, will enhance AC-mediated immunosuppression of AMs. It would be interesting to test whether increased immunosuppression from ACs within the lung may explain these opposing results between COPD patients and model systems regarding ICs use and pneumonia, particularly for emphysema patients where lung destruction generates large numbers of ACs. Our finding that murine AMs efferocytosis is increased after GC, azithromycin, or simvastatin treatment demonstrates that mice provide an appropriate model system with which to predict consequences of pharmacologically augmented AC clearance on human lung disease.

In summary, to our knowledge, our study demonstrates for the first time that GCs increase AC uptake by murine AMs. We provide evidence that this rapid increase is caused by disruption of collectin-SIRPα signaling through downregulation of SIRPα transcript and surface protein, a novel GC mechanism. Finally, we demonstrate that regulation of AC uptake by SIRPα is not restricted to AMs and can be activated in PMs after exposure to SP-D.

Acknowledgments

We thank Drs. David M. Aronoff, Jean-François Cailhier, Johanna Floros, Peter Mancuso, Peter M. Henson, Joel A. Swanos, Debra A. Thompson, and Jill C. Todt for helpful discussion and suggestions.

Disclosures

The authors have no financial conflicts of interest.

References
